We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation.
- Authors
Bates, Jill S; Auten, Jessica; Sketch, Margaret R; Patel, Tejendra; Clark, Stephen Michael; Morgan, Katherine P; Muluneh, Benyam; McLaughlin, Jacqueline E; Pinelli, Nicole R; Foster, Matthew C; Amerine, Lindsey
- Abstract
Background: Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the patient activation measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during a patient encounter at the beginning of the patient's treatment for cancer. Methods: This was a single center, prospective, non-randomized, observational clinical study in patients with cancer who required a new chemotherapy plan. A baseline patient activation measure-10 survey was administered and a pharmacy team member met with the patient to complete the first cycle 3CS encounter. Within two business days of that encounter, a second patient activation measure-10 survey was administered, and thus, patients served as their own control. Results: Forty-nine patients who met the inclusion criteria were enrolled, of which 36 completed the study. Mean patient activation measure-10 scores measured at baseline and two business days after the 3CS encounter were significantly different (68.5 ± SD 14.7 vs. 75.0 ± SD 14.3, p = 0.001). This difference persisted when evaluated by gender (female: 70.0 ± SD 14.8 vs. 81.6 ± SD 10.5, p = 0.001; male: 66.1 ± SD 14.8 vs. 70.8 ± SD 14.7, p = 0.022). Conclusion: This study demonstrates that cancer patients had significantly increased patient activation scores after engagement in a 3CS encounter provided by an oncology pharmacy team. Further studies are needed to verify these data in a larger population, different healthcare settings, and to evaluate for patients who have solid tumor malignancies.
- Subjects
ANTINEOPLASTIC agents; CANCER chemotherapy; CANCER patients; LONGITUDINAL method; MEDICAL referrals; SCIENTIFIC observation; PATIENT education; PHARMACISTS; SURVEYS; PATIENT participation; PSYCHOSOCIAL factors; DESCRIPTIVE statistics
- Publication
Journal of Oncology Pharmacy Practice, 2019, Vol 25, Issue 4, p896
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/1078155219832644